ANTHEM · NSE
Anthem Biosciences Limited
₹928.5
+0.12% (+₹1.1)
Prev. close
₹927.4
Volume
54,90,000
Delivery %
69.5%
As of
18 Sept 2026
Price history
Analyst sentiment
Analysts lean bullish
1 analyst stance · last 90 days · one per analyst
Trackable
1 · 1 bull / 0 neutral / 0 bear
Long-Horizon
none in window
Commentary
none in window
Trackable = verdict-bearing calls · Long-Horizon = 1yr+ horizon, verdict pending · Commentary = context, not graded
Analyst opinions
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Initiated coverage on Anthem Biosciences with a 'buy' rating and a price target of ₹1,050 per share, implying a 20% upsi…” | Jefferies AnalysisJefferies | Anthem Biosciences | PENDING |
Fundamentals
About Anthem Biosciences Limited
Anthem Biosciences Limited operates as a contract research, development, and manufacturing organization in India, rest of Asia, North America, Europe, and internationally. It operates in two segments: Contract Manufacturing, Development & Discovery Services; and Speciality Ingredients. The company offers contract research development and manufacturing services, such as end-to-end services across the new chemical entity and new biological entity lifecycles, as well as engages in contract research, development, and manufacturing of development batches of molecules used for clinical trials up to commercial manufacturing for small molecules and biologics. It also manufactures and sells specialized fermentation-based active pharmaceutical ingredients, including probiotics, enzymes, peptides, nutritional actives, vitamin analogues, and biosimilars. The company was incorporated in 2006 and is based in Bengaluru, India.
Details
Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Ajay Bhardwaj B.Tech., M.S
Headquarters
Bengaluru
Employees
2,282
Website
anthembio.comExchange
View on NSE ↗Key stats
Market cap
₹52,155.13 Cr
P/E ratio (TTM)
91.8
Dividend yield
0.22%
EPS (TTM)
₹10.11
Beta (1Y · daily vs NIFTY 50)
0.57
Shares float
7.19 Cr
EPS · quarter ended Jun 2026
₹2.11
Financial Performance
01 · Financials
FY21 growth needs FY20 filings, which the data source doesn't provide. Net income and EBITDA are omitted from this chart: coverage begins inside the plotted window, and every plotted period must carry a complete point set — the P&L table below has the available figures.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹1,056.92 Cr | ₹1,419.37 Cr | ₹1,844.55 Cr | ₹2,124.33 Cr | |
| EBITDA | — | — | ₹569.27 Cr | ₹568.42 Cr | ₹756.26 Cr | ₹965.20 Cr |
| — | — | ₹385.19 Cr | ₹367.31 Cr | ₹451.26 Cr | ₹591.79 Cr | |
| Diluted EPS | — | — | ₹6.86 | ₹6.54 | ₹8.04 | ₹10.43 |
Revenue, Total expenses (as filed), Employee benefit expense, Other expenses, EBITDA, Net income, Tax provision, Other income, Diluted EPS have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹1,034.00 Cr | ₹1,619.00 Cr | ₹2,014.00 Cr | ₹2,398.00 Cr | ₹2,808.00 Cr | ₹3,429.00 Cr | |
| — | — | ₹126.15 Cr | ₹238.52 Cr | ₹113.32 Cr | ₹53.92 Cr | |
| Stockholders' equity | ₹701.00 Cr | ₹1,355.00 Cr | ₹1,741.00 Cr | ₹1,925.00 Cr | ₹2,410.00 Cr | ₹3,042.00 Cr |
Current assets, Inventory, Trade receivables, Cash & equivalents, Non-current assets, CWIP, Others, Total debt, Long-term debt, Current (short-term) debt have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹278.00 Cr | ₹333.00 Cr | ₹306.00 Cr | ₹140.00 Cr | ₹271.00 Cr | ₹844.00 Cr | |
| Investing cash flow | — | — | ₹-376.02 Cr | ₹-221.46 Cr | ₹-146.57 Cr | ₹-701.62 Cr |
| ₹-63.00 Cr | ₹181.00 Cr | ₹64.00 Cr | ₹-77.00 Cr | ₹-136.00 Cr | ₹-40.00 Cr | |
| Capital expenditure | ₹-120.00 Cr | ₹-26.00 Cr | ₹-184.00 Cr | ₹-117.00 Cr | ₹-261.00 Cr | ₹-211.00 Cr |
| End cash position | — | — | ₹342.85 Cr | ₹184.36 Cr | ₹172.28 Cr | ₹274.88 Cr |
Investing cash flow, Dividends paid, End cash position have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Jul 25–Dec 25(3Q) | Mar 26 | Jun 26 |
|---|---|---|---|
| Promoter | 74.69% | 74.68% | 71.42% |
| Public | 25.31% | 25.32% | 28.58% |
| Employee trusts | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Anthem Biosciences Limited | ₹51,028.90 Cr | ₹927.4 | 90.0 | 16.77 | 19.5% | 0.02 | +15.2% | +7.3% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
IPO documents
Annual reports
Concall transcripts
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
22 indices
NSE weights are a free-float market-cap-share estimate, not NSE’s own published (and sometimes capped) index weight. BSE weights are BSE’s own published index weight, not an estimate. Indices without weight data are listed without one, in alphabetical order after the weighted ones.
Jefferies initiates coverage on Anthem Biosciences with a Rs 1,050 target
Jefferies initiated coverage on Anthem Biosciences with a Buy rating and a price target of Rs 1,050, implying a 20% upside. The brokerage cited the company's differentiated capabilities in small- and large-molecule therapeutics, strong return ratios, and healthy growth prospects. Jefferies expects Anthem's revenue to grow at an 18% CAGR between FY26 and FY29, driven by its integrated CRDMO model.